Showing 7971-7980 of 8628 results for "".
- One Quarter of Americans Misled by Online Info: Surveyhttps://practicaldermatology.com/news/one-quarter-of-americans-misled-by-online-info-survey/2458841/One in four Americans (24 percent) say they have been misled by information about an illness or medical symptom from an unverified online source, according to a new survey from Merck Manuals. That figure increases to 30 percent among parents with children under 18 and jumps to 43 percent among mi
- LEO Pharma Inc. Announces FDA Approval of Enstilar Foam for Plaque Psoriasishttps://practicaldermatology.com/news/leo-pharma-inc-announces-fda-approval-of-enstilar-foam-for-plaque-psoriasis/2458842/The FDA approved LEO Pharma Inc’s Enstilar for the topical treatment of plaque psoriasis in adults 18 years of age and older. Enstilar is a once-daily, alcohol free foam formulation in a pressurized spray can that allows application across large body areas of plaque psoriasis. In th
- RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109https://practicaldermatology.com/news/rxi-pharmaceuticals-announces-positive-interim-results-in-phase-2a-dermatology-program-with-rxi-109/2458844/RXi Pharmaceuticals Corporation shared results from a blinded panel and an Investigator review showing that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.</
- Study Demonstrates Duac Significantly Reduces Inflammatory Acne Lesionshttps://practicaldermatology.com/news/study-demonstrates-duac-significantly-reduces-inflammatory-acne-lesions/2458846/Stiefel shared the findings of a head-to-head German study demonstrating that, in patients with mild-to-moderate acne vulgaris, treatment with Duac™ 3% (benzoyl peroxide 3% + clindamycin 1%) led to numerically fewer inflammatory and non-inflammatory lesions from baseline compared to treatme
- A Novel Dual-Wavelength, Nd:YAG, Picosecond-domain Laser Safely and Effectively Removes Multicolor Tattooshttps://practicaldermatology.com/news/a-novel-dual-wavelength-ndyag-picosecond-domain-laser-safely-and-effectively-removes-multicolor-tattoos/2458848/Research conducted by Eric F. Bernstein MD, MSc; Kevin T. Schomacker PhD; Lisa D. Basilavecchio RN; Jessica M. Plugis; and Jayant D. Bhawalkar PhD, published in the September 2015 issue of Lasers in Surgery and Medicine (LSM), evaluated 21 tattooed subjects between the ages of 19-55 who
- FDA Accepts sNDA for Dalvancehttps://practicaldermatology.com/news/fda-accepts-snda-for-dalvance/2458849/The FDA accepted Allergan's supplemental New Drug Application (sNDA) to expand the label to include single-dose administration of DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults caused by design
- Syneron Introduces PicoWay Resolvehttps://practicaldermatology.com/news/syneron-introduces-picoway-resolve/2458850/Syneron Medical Ltd. introduced the PicoWay Resolve™, a dual wavelength fractional modality for the PicoWay picosecond laser, at the 24th European Academy of Dermatology and Venereology (EADV) Congress in Copenhagen, Denmark, October 7-11, 2015. The launch of the new Resolve frac
- Aclaris Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/aclaris-announces-pricing-of-initial-public-offering/2458854/Aclaris Therapeutics, Inc. announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $11.00 per share. The shares, approved for listing on The NASDAQ Global Select Market, will be traded under the ticker symbol ACRS. All of the common
- Dermira Presents Data From DRM01 Phase 2a Trial at European Academy of Dermatology and Venereologyhttps://practicaldermatology.com/news/dermira-presents-data-from-drm01-phase-2a-trial-at-european-academy-of-dermatology-and-venereology/2458853/Topline data from a Phase 2a study showed that Dermira’s DRM01, a novel topical sebum inhibitor in development for the treatment of acne, met all of the primary efficacy endpoints, demonstrating statistically significant improvements relative to vehicle in the reduction of lesion counts and
- 100,000 Join the ASPIRE Galderma Rewards Loyalty Program in First 90 dayshttps://practicaldermatology.com/news/100000-join-the-aspire-galderma-rewards-loyalty-program-in-the-first-90-days/2458867/Galderma’s ASPIRE Rewards program has enrolled 100,000 consumers since its launch on May 1, 2015. ASPIRE Galderma Rewards is a new loyalty program connecting US consumers and healthcare professionals using the Galderma family of aesthetic products. The vision of the Galderma a